BioCentury | Jun 17, 2013
Financial News

Genmab financial update

...Genmab said that Meditor Capital Management sold its more than 5% stake in the biotech. Genmab...
BioCentury | Jun 17, 2013
Finance

Highlights of weekly biotech stock moves

...one year. Genmab A/S (CSE:GEN; OTCBB:GMXAY) fell DKK30.10 (14%) to DKK184.50 last week after announcing Meditor...
BioCentury | Jan 31, 2011
Company News

BrainStorm management update

...York, N.Y. Business: Neurology Hired: Adrian Harel as COO and acting CEO, formerly CEO of Meditor Pharmaceuticals Ltd....
BioCentury | Jun 16, 2008
Clinical News

MTR106: Additional Phase II data

...improved pain relief vs. placebo at 2 hours after dosing (see BioCentury, Nov. 12, 2007). Meditor Pharmaceuticals Ltd....
BioCentury | May 19, 2008
Company News

Meditor management update

Meditor Pharmaceuticals Ltd. , Rehovot, Israel Business: Cardiovascular Hired: Adrian Harel as CEO WIR Staff Cardiovascular...
BioCentury | Nov 12, 2007
Clinical News

MTR106: Phase II data

...met the primary endpoint of superiority to placebo in reducing migraine intensity within 2 hours. Meditor Pharmaceuticals Ltd....
BioCentury | Nov 8, 2007
Clinical News

Meditor's MTR106 meets migraine endpoint

Meditor (Rehovot, Israel) said all four doses of MTR106 met the primary endpoint of superiority to placebo in reduction of intensity of migraine within two hours in a Phase II trial to treat acute migraine...
BioCentury | Aug 24, 2007
Financial News

Inotek raises $19.3 million

...Mass.) raised $19.3 million in a series C round. New investors Hercules Technology Growth Capital; Meditor...
BioCentury | May 8, 2006
Finance

Europe’s Iceberg 2006

...have been attracted to the sector, such as Healthcor, MKM Longboat, RAB Capital, Mac Capital, Meditor...
BioCentury | Apr 24, 2006
Clinical News

MTR 104: Phase II started

...began a double-blind Phase II trial with MTR 104 in CRF patients with intradialytic hypotension. Meditor Pharmaceuticals Ltd....
Items per page:
1 - 10 of 11
BioCentury | Jun 17, 2013
Financial News

Genmab financial update

...Genmab said that Meditor Capital Management sold its more than 5% stake in the biotech. Genmab...
BioCentury | Jun 17, 2013
Finance

Highlights of weekly biotech stock moves

...one year. Genmab A/S (CSE:GEN; OTCBB:GMXAY) fell DKK30.10 (14%) to DKK184.50 last week after announcing Meditor...
BioCentury | Jan 31, 2011
Company News

BrainStorm management update

...York, N.Y. Business: Neurology Hired: Adrian Harel as COO and acting CEO, formerly CEO of Meditor Pharmaceuticals Ltd....
BioCentury | Jun 16, 2008
Clinical News

MTR106: Additional Phase II data

...improved pain relief vs. placebo at 2 hours after dosing (see BioCentury, Nov. 12, 2007). Meditor Pharmaceuticals Ltd....
BioCentury | May 19, 2008
Company News

Meditor management update

Meditor Pharmaceuticals Ltd. , Rehovot, Israel Business: Cardiovascular Hired: Adrian Harel as CEO WIR Staff Cardiovascular...
BioCentury | Nov 12, 2007
Clinical News

MTR106: Phase II data

...met the primary endpoint of superiority to placebo in reducing migraine intensity within 2 hours. Meditor Pharmaceuticals Ltd....
BioCentury | Nov 8, 2007
Clinical News

Meditor's MTR106 meets migraine endpoint

Meditor (Rehovot, Israel) said all four doses of MTR106 met the primary endpoint of superiority to placebo in reduction of intensity of migraine within two hours in a Phase II trial to treat acute migraine...
BioCentury | Aug 24, 2007
Financial News

Inotek raises $19.3 million

...Mass.) raised $19.3 million in a series C round. New investors Hercules Technology Growth Capital; Meditor...
BioCentury | May 8, 2006
Finance

Europe’s Iceberg 2006

...have been attracted to the sector, such as Healthcor, MKM Longboat, RAB Capital, Mac Capital, Meditor...
BioCentury | Apr 24, 2006
Clinical News

MTR 104: Phase II started

...began a double-blind Phase II trial with MTR 104 in CRF patients with intradialytic hypotension. Meditor Pharmaceuticals Ltd....
Items per page:
1 - 10 of 11